BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 21233451)

  • 1. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.
    Toyoda T; Kamei Y; Kato H; Sugita S; Takeya M; Suganami T; Ogawa Y
    Obesity (Silver Spring); 2008 Jun; 16(6):1199-207. PubMed ID: 18356826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone upregulates adiponectin receptor 2 in 3T3-L1 adipocytes.
    Kudoh A; Satoh H; Hirai H; Watanabe T
    Life Sci; 2011 Jun; 88(23-24):1055-62. PubMed ID: 21514306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
    Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nifedipine, a calcium-channel blocker, attenuated glucose intolerance and white adipose tissue dysfunction in type 2 diabetic KK-A(y) mice.
    Iwai M; Kanno H; Inaba S; Senba I; Sone H; Nakaoka H; Horiuchi M
    Am J Hypertens; 2011 Feb; 24(2):169-74. PubMed ID: 20847723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Carotene accumulation in 3T3-L1 adipocytes inhibits the elevation of reactive oxygen species and the suppression of genes related to insulin sensitivity induced by tumor necrosis factor-α.
    Kameji H; Mochizuki K; Miyoshi N; Goda T
    Nutrition; 2010; 26(11-12):1151-6. PubMed ID: 20097535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice.
    Verreth W; De Keyzer D; Pelat M; Verhamme P; Ganame J; Bielicki JK; Mertens A; Quarck R; Benhabilès N; Marguerie G; Mackness B; Mackness M; Ninio E; Herregods MC; Balligand JL; Holvoet P
    Circulation; 2004 Nov; 110(20):3259-69. PubMed ID: 15533870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.
    Powell LA; Crowe P; Kankara C; McPeake J; McCance DR; Young IS; Trimble ER; McGinty A
    Clin Sci (Lond); 2012 Aug; 123(3):135-46. PubMed ID: 22309242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
    Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
    Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of adiponectin by natural and synthetic phenolamides in mouse and human preadipocytes and its enhancement by docosahexaenoic acid.
    Yamazaki Y; Kawano Y; Uebayasi M
    Life Sci; 2008 Jan; 82(5-6):290-300. PubMed ID: 18166202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage-derived apolipoprotein E ameliorates dyslipidemia and atherosclerosis in obese apolipoprotein E-deficient mice.
    Atkinson RD; Coenen KR; Plummer MR; Gruen ML; Hasty AH
    Am J Physiol Endocrinol Metab; 2008 Feb; 294(2):E284-90. PubMed ID: 18029445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of pioglitazone on visfatin expression in 3T3-L1 adipocytes and SD rats.
    Lv Q; Wang Y; Wang W; Wang L; Zhou X
    Endocr Res; 2009; 34(4):130-41. PubMed ID: 19878073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation.
    Hansmann G; Wagner RA; Schellong S; Perez VA; Urashima T; Wang L; Sheikh AY; Suen RS; Stewart DJ; Rabinovitch M
    Circulation; 2007 Mar; 115(10):1275-84. PubMed ID: 17339547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice.
    Mohapatra J; Sharma M; Singh S; Chatterjee A; Swain P; Balaraman R; Patel PR; Jain MR
    Pharmacology; 2009; 84(4):203-10. PubMed ID: 19738399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
    Liu LF; Purushotham A; Wendel AA; Belury MA
    Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.